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Patients undergoing hematopoietic stem cell transplanta­
tion have an increased risk of late complications including 
skin cancer. The diagnosis of melanoma and atypical mela­
nocytic lesions in patients with chronic cutaneous graft ver­
sus host disease is challenging, as the alteration of the skin 
associated with the disease may mimic malignant dermos­
copic findings in benign melanocytic naevi. We evaluated 
110 melanocytic lesions and found a significant associa­
tion between signs of regression and a high score of ma­
lignancy. We believe that digital follow-up and comparative 
analyses reduce the number of excised melanocytic lesions 
which exhibit marked structural and colour changes similar 
to melanoma.
Patients treated with haematopoietic stem cell trans-
plantation are at increased risk of cutaneous malignant 
neoplasms. There are no reports on the characteristics 
of melanocytic lesions in patients with chronic graft 
versus host disease and the value of recognizing these 
difficult lesions in high-risk patients. The objective of 
this study is to describe the clinical and dermo scopic 
characteristics of melanocytic lesions in patients 
with chronic graft versus host disease in order to un-
derstand their morphology. A prospective cross-sec-
tional study was performed; 10 melanocytic lesions on 
the trunk and extremities were selected from each pa-
tient. A statistically significant association was found 
between regression and high total dermoscopic score 
and 7-point checklist score. Lesions were excised or in-
cluded in short-term digital follow-up. Melanocytic le-
sions in patients with chronic graft versus host disease 
developing after allogeneic-haematopoietic stem cell 
transplantation exhibit marked structural and colour 
changes similar to melanoma. This is believed to result 
from the inflammatory process associated with graft 
versus host disease. 
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Patients undergoing haematopoietic stem cell trans-plantation (HSCT) are at increased risk of late 
complications. Survival of these patients has improved 
over time, but is associated with the development of 
secondary malignacies, including cutaneous malignant 
neoplasms. In particular, non-melanoma skin cancer is 
clearly increased in this group of patients, as is mela-
noma, and together, these may represent up to one-third 
of all malignancies in these patients (4).
Chronic graft versus host disease (cGVHD) is a high-
risk complication of allogeneic HSCT. In cGVHD there 
is an activation of T-cell lymphocytes, with consequent 
inflammation of the skin and other organs producing 
different clinical manifestations. The muco-cutaneous 
manifestations of cGVHD can be divided into sclero-
dermiform and non-sclerodermiform (5). The cutaneous 
inflammation induces changes in melanocytic lesions 
and architectural modifications (6). These alterations 
are responsible for the atypical features in melanocytic 
lesions of patients with cGVHD and can make clinical 
diagnosis challenging. In patients with multiple naevi, 
the comparative analyses approach is used to reduce the 
number of excisions and detect melanomas, reducing 
the number needed to treat (7). Dermoscopy improves 
the diagnostic accuracy of skin cancer and is used as an 
adjunct to clinical examination in clinical practice. Di-
gital follow-up of patients with atypical mole syndrome 
reduces the number of skin biopsies of benign lesions and 
detects early melanoma in these patients (8). However, 
the impact of dermoscopy and digital dermoscopy has 
not been described in patients with cGVHD. 
MATERIALS AND METHODS
Patients and lesions
Eleven consecutive patients with a personal history of active 
cGVHD, aged between 18 and 70 years, with more than 50 naevi, 
who were attending the Dermatology Clinic for GVHD were 
consecutively included in a prospective cross-sectional study of 
melanocytic skin lesions. Inclusion criteria were the presence of 
multiple melanocytic lesions on the trunk and limbs, a previous 
HSCT, and the presence of active cutaneous cGVHD. Inclusion 
criteria for the lesions were the 10 largest lesions in the patient, all 
being larger than 2 mm. Ulcerated or eroded melanocytic lesions 
and lesions located on special sites (head and neck area, acral sites, 
and genitalia) were excluded from the study. 
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Clinical/dermoscopic examination
Evaluation was performed clinically and via dermoscopy (Derm-
lite; 3GEN LLC; Salvador Bay, Dana Point, CA, USA), Molemax 
HD (Derma Medical Systems, Vienna, Austria). Clinical and 
dermoscopic images were taken using a digital camera (Canon 
PowerShot G16 (Canon Hongkong Co., Ltd) and a cross-polarized 
light dermatoscope (DermlitePhoto; 3GEN, LLC). 
Evaluation included age, sex, anatomical location, skin type, 
skin cancer history and number of naevi. Anatomically, the lesions 
were classified as on the chest, abdomen, back, upper limbs or 
lower limbs. Dermoscopic features were described according 
to the third consensus of the International Dermoscopy Society 
(IDS) (9), ABCD-total dermoscopic score (TDS) (10) and the 
7-point-checklist score were assessed (11). For the TDS score 
(A*1.3 + B*0.8 + C*0.5 + D*0.5) the criteria evaluated were A 
for asymmetry in 1 or 2 axes; B for 1˗8 borders abrupt cut-off; C 
for colours (white, red, light-brown, dark-brown, blue-grey, black) 
and D for different structural components (structureless areas, 
pigment network, branched streaks, dots, and aggregate globu-
les). Lesions with less than 4.75 points were considered benign, 
between 4.75 and 5.45 points were considered suspicious, and 
more than 5.45 points malignant. For the classic scoring system 
of the 7-point checklist, 3 major criteria have a score of 2 points 
each (atypical network, blue-white veil and atypical vascular pat-
tern) and 4 minor criteria have a score of 1 point each (irregular 
dots/globules, irregular streaks, irregular blotches and regression 
structures); lesions with a total score of 3 or more are judged to 
merit excision. For statistical analysis, the dermoscopic global 
pattern was divided into 5 groups, as follows: 1: predominantly 
reticular: reticular, reticular homogeneous, pseudo reticular; 2: 
predominantly globular: globular, reticular globular, globular 
homogeneous; 3: homogeneous and unspecific; 4: starburst; and 
5: multicomponent. Patients were followed-up every 6 months 
with digital dermoscopy. Short-term digital dermoscopy follow-up 
of 3 months in equivocal lesions was performed according to the 
investigator’s criteria (12). 
Evaluation
The lesions were evaluated by a single investigator with experience 
in dermoscopy and digital follow-up (A.B.).
Criteria for excision
Excision criteria were: lesions with clear criteria of malignancy; 
significant changes in short-term digital follow-up; or when the 
investigators considered the need for excision after comparative 
analysis of the lesions of every patient (7, 13–15).
Statistical analysis 
Statistical analysis was performed using PASW Statistics 22.0 
software (SPSS, Chicago, IL, USA). The χ2 test was used for the 
comparison of qualitative variables (Fisher’s exact test was applied 
if any expected cell value in the 2×2 table was < 5). Differences 
were considered to be statistically significant when p-value was 
less than 0.05. 
RESULTS
The cohort consisted of 110 melanocytic lesions in 11 
patients. The mean ± standard deviation (SD) age of the 
patients was 49.45 ± 9.6 years at time of inclusion, 72.7% 
were men (n = 8) (Table I). 
Three patients had acute myeloid leukaemia, 2 had 
mantle cell lymphoma, 2 had Philadelphia-positive 
chronic myeloid leukaemia, 2 had acute lymphoblastic 
leukaemia, one had follicular lymphoma, and one had 
multiple myeloma. Five patients received conditioning 
based on total body irradiation plus cyclophosphamide, 
while the remaining 6 patients received combination 
chemotherapy. All patients had received allo-HSCT and 
only 3 patients were not donor related.
Of the 11 patients evaluated, 6 had both subtypes of 
cGVHD (lichenoid and sclerodermiform), 3 were liche-
noid and 2 were sclerodermiform. 
Lesions were located as follows: 50 (45.5%) on the 
back, 20 (18.2%) on the abdomen, 17 (15.5%) on upper 
extremities, 13 (11.8%) on the chest, 10 (9.1%) on lower 
extremities. No lesions from the head and neck area, 
acral skin, genital mucosa or other special locations as 
flexural sites were included. 
Nine patients had Fitzpatrick skin phototype III and the 
remaining 2 patients had skin phototype II. Four of the 
11 patients had a personal history of skin cancer (2 had 
basal cell carcinoma and 2 had squamous cell carcinoma). 
All the patients included in the study had a naevi count 
of between 50 and 100. 
The largest size of the lesions was 12 mm and the 
smallest 2 mm (mean 3 mm). The codified global der-
moscopic pattern was predominantly reticular (reticular, 
reticulo-homogeneous or pseudoreticular pattern) in 50% 
(n = 55); homogeneous or unspecific in 36.4% (n = 40); 
and predominantly globular (globular, globular reticular 
or globular homogeneous) in 13.6% (n = 15). No lesions 
with starburst and multicomponent patterns were found.
Dermoscopic evaluation showed dots and globules in 
30% (n = 33) of the lesions and 91% (n = 30) of them were 














  M 8 (72.7) 49.45 19 (17.2) 13 (11.8) 65 (59.1) –
  F 3 (27.3)
1 F 42 1 1 9 –
2 M 51 1 2 7 –
3 M 50 2 0 5 Lentiginous
4 M 45 2 0 4 Naevi of special 
sites
5 M 54 0 1 5 –
6 F 63 1 2 7 Naevi of special 
sites
7 M 32 3 1 4 Lentiginous
8 F 65 3 0 5 –
9 M 57 1 1 3 –
10 M 37 2 3 4 Naevi of special 
sites
11 M 49 3 2 2 Naevi with 
regression
Naevi of special sites are a group of naevi that can simulate both dysplastic naevi 
and melanomas. These lesions may show architectural features overlapping with 
melanoma. Usually are at genital area, acral and flexural sites, and in naevi of 
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atypical. Streaks were present in only 7.3% (n = 8) of the 
lesions and atypical pigment network in 50.9% (n = 56). 
Blotching with irregular distribution was present in 20% 
(n = 22). Regression criteria (blue/grey and white) were 
seen in 78.2% of the lesions (n = 86) (Table II).
According to the TDS rule, 19 pigmented lesions 
with a score of suspicious (17.2%) and 13 (11.8%) with 
a score higher than 5.45 (classified as malignant) were 
found. The mean ± SD TDS of the lesions was 3.95 ± 1.4. 
The 7-point checklist resulted in 59.1% (n = 65) of the 
lesions with a score of 3 or more and the mean ± SD score 
was 2.58 ± 1.4.
Blue-grey regression (Fig. 1) was present in all the 
lesions with a TDS of malignancy (p = 0.024) and in 
93.8% of the lesions with 3 or more points in the 7-point 
check-list (p = 0.000) (Table III). White regression was 
described in 68.4% (n = 13) of the tumours with “sus-
picious TDS” (p = 0.000) and in 89.5% (n = 17) of the 
lesions with more than 2 points on the 7-point check-list 
(p = 0.002).
Almost 60% (n = 10) of the lesions with mixed reg-
ression (blue-grey regression and white regression) had 
suspicious TDS (p = 0.007) and 82.4% (n = 14) of lesions 
with this kind of dermoscopy pattern presented more than 
3 points in the 7-point check-list (p = 0.029).
Regarding dots and globules, 93.9% of the naevi 
with this dermoscopy sign had a high score (>2) in the 
7-point checklist (p = 0.000). All the lesions with atypical 
dots and globules had more than 2 points in the 7-point 
check-list (p = 0.000). 
As regards the score suggesting malignancy in the 
7-point checklist, 80.4% of the lesions had atypical 
pigment network (p = 0.000), 100% of the lesions had 
atypical streaks (p = 0.000), and 86.4% of the lesions had 
atypical blotches (p = 0.003). 
Rosettes and negative pigment network were not seen 
in any of the lesions. 
Six atypical lesions in 6 patients (5.4% of all the lesions 
in this study) had a TDS consistent with melanoma and 
were excised (Fig. 2) with a pathological result of benign 
naevi with some atypia, inflammation or regression, but 
none proved to be malignant melanoma. The remaining 
lesions were included in a short-term dermoscopy digital 
follow-up of 3 months and were not excised, as no signi-




Typical, n Atypical, n
Specific pattern
Pigment network 9 56
Dots and globules 3 30
Blotch 21 22
Streaks   3   5
Blue regression 84
White regression 19
Blue and white regression 17
Blue whitish veil –
Negative pigment network –
Annular granular pattern 3
Irregular perifollicular pigmentation 2
Short white streaks 1
Rosettes –












Pseudoreticular   4
Table III. Correlation between dermoscopy criteria, total 








Absent/typical 16 (29.6) 0.77 20 (37) 0.000
Atypical 18 (32.1) 45 (80.4)
Atypical dots/globules
Absent/typical 23 (28.7) 0.42 35 (43.8) 0.000
Atypical 11 (36.7) 30 (100)
Atypical blotch
Absent/regular 27 (30.7) 0.91 46 (52.3) 0.003*
Irregular   7 (31.8) 19 (86.4)
Atypical streaks
Absent/typical 23 (28.7) 0.42 35 (43.8) 0.000
Atypical 11 (36.7) 30 (100)
Blue/grey regression
Absent   5 (19.2) 0.14   4 (15.4) 0.000*
Present 29 (34.5) 61 (72.6)
White regression
Absent 21 (23.1) 0.00 48 (52.7) 0.002*
Present 13 (68.4) 17 (89.5)
Mixed regression
Absent 24 (25.8) 0.007 51 (54.8) 0.029*
Present 10 (58.8) 14 (82.4)
*Fisher’s test was applied. Significant values are shown in bold.
Fig. 1. (a) Clinical image of an atypical lesion. (b) Dermoscopy 
(x30) shows  atypical pigment network, structureless areas 
(arrow) and the presence of regression (blue/grey) at the centre 
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ficant changes were observed. Patients were followed-up 
every 6 months with total body dermoscopy and digital 
dermoscopy of all included non-excised lesions. None 
of the patients developed melanoma (mean follow-up 
12 months) (Fig. 3).
DISCUSSION
Patients undergoing HSCT often develop cutaneous cG-
VHD and will need dermatological care in specialized 
units for better management and control. These patients 
have an increased risk for skin cancer (2, 16). Several risk 
factors for squamous cell carcinoma, basal cell carcinoma 
and melanoma in HSCT recipients have been identified. 
The association between cutaneous malignant neoplasm 
development and cGVHD is poorly understood; however, 
cutaneous malignant neoplasm often develop at sites of 
previous cGVHD (17).
There is a lack of systematic description in the scien-
tific literature of melanocytic lesions in patients who de-
velop cGVHD after HSCT. In 2002, Andreani et al. (18) 
described the number of naevi in allogeneic bone marrow 
transplantation recipients. They found that conditioning 
with high-dose chemotherapy, absence of severe cuta-
neous cGVHD, and young age at transplantation were the 
main variables that independently predicted an excess of 
naevi; but they did not describe the dermoscopy of these 
lesions (18). In another paper, Kaminska-Winciorek et 
al. (19) reported the dermoscopic features and follow-up 
of 13 patients with acute GVHD. 
The current study describes, for the first time, the 
dermoscopic characteristics of melanocytic lesions 
Fig. 2. (a) Clinical image of the abdomen of the patient.  The 
evolution of this lesion was unknown and it was very different 
from the others.  (b) Dermoscopy (x30) shows an atypical highly 
pigmented lesion. (c) Large nests of melanocytic cells were seen 
in the superficial dermis. Fibroplasia and abundant melanophages 
are also observed (haematoxylin and eosin; HE×100).
Fig. 3. Pigmented lesion with structureless areas (arrow) and regression signs (circled). Short-term digital follow-up showed no changes (30x). 
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in patients with cGVHD. In our patients we found a 
high percentage of benign lesions with malignant or 
suspicious scores in TDS and the 7-point check-list in 
the same patient. The higher scores of malignancy of 
lesions in patients with cGVHD are probably due to the 
inflammatory process of the skin (20). These lesions 
exhibited significant regression (80%) and atypical 
pigment network (51%), which are criteria associated 
with melanoma. Differences were found between both 
methods (TDS and 7-point checklist), which can be 
explained by the fact that the 7-point and the TDS score 
evaluate structures and colours in a different way. Also, 
in the 7-point checklist the impact of atypical pigment 
network and regression structures is higher in the final 
score than in the ABCD rule (10, 11).
Dermoscopy, digital dermoscopy follow-up and 
comparative analyses are important tools for evaluating 
difficult melanocytic skin lesions (7, 8). In complicated 
cases, such as patients with atypical mole syndrome, the 
comparative analysis is highly sensitive for detecting 
melanoma. Moreover, digital dermoscopy follow-up has 
been introduced for the monitoring of patients at high 
risk of melanoma, such as in atypical mole syndrome, 
familial melanoma syndrome or patients with xeroderma 
pigmentosum. Using these methods early melanoma can 
be detected, thus reducing the number of unnecessary 
excisions of equivocal benign lesions (8).
The efficiency of digital dermoscopy for the detec-
tion of early melanomas in high-risk patients, such as in 
patients with xeroderma pigmentosum (21, 22), those 
receiving anti-BRAF treatment (23–25), and atypical 
mole syndrome, has been assessed. Salerni et al. (8) in a 
meta-analysis of digital follow-up concluded the utility 
of short-term monitoring in patients with atypical mole 
syndrome. Perier-Muzet et al. (24) published a prospec-
tive follow-up, by digital dermoscopy, of melanocytic 
lesions in patients under vemurafenib treatment. They 
reported that more than 50% of the captured lesions sho-
wed changes induced by the drug and that these changes 
occurred very rapidly (approximately 32.6% by the third 
month after initiation of treatment). The dermoscopic 
criteria that led to surgical removal in these cases were: 
localized changes in focal pigmentation (“dermoscopic 
islands”), the appearance of dark structureless areas, and 
changes in network or in diameter. In contrast to our 
study of cGVHD patients, they concluded that standard 
recommendations regarding digital follow-up could not 
be applied in patients receiving BRAF inhibitors. 
In the current study the use of comparative analyses 
and digital follow-up were useful to manage the atypi-
cal lesions in patients with cGVHD without excision of 
many benign naevi. Short-term follow-up did not show 
significant dermoscopic changes at the 3-month period.
Regarding the histopathology of these lesions, features 
of naevi were found at special sites in 3 of the 6 biopsies, 
with the presence of dermal fibroplasia and large nests in 
the superficial dermis and at the dermal epidermal jun-
ction. Extensive regression was found in one lesion. The 
remaining 2 lesions had a lentiginous pattern of growth. 
Naevi of special sites or naevi with site-related atypia 
can show unusual histopathological features that mimic 
dysplastic naevi and malignant melanoma. However, 
changes of pseudomelanoma, which are frequently seen 
in recurrent naevi, or subepidermal clefts of epidermoly-
sis bullosa-associated naevi were not found. The cause of 
these variations is not known, but it has been suggested 
that external factors (i.e. trauma, ultraviolet radiation) or 
intrinsic factors (i.e. age, hormonal factors) could play a 
role in their development (26, 27).
In conclusion, the diagnosis of melanoma and atypical 
melanocytic lesions in patients with cutaneous cGVHD 
patients is challenging as the alteration of the skin as-
sociated with the disease induces atypical dermoscopic 
findings in benign melanocytic naevi. Digital follow-up 
and comparative analyses (ugly duckling sign) were 
useful in reducing the number of excisions in our pa-
tients. In the future, other modern technologies, such as 
reflectance confocal microscopy (28–30) or electrical 
impedance spectroscopy (31) may be useful to improve 
the accuracy of clinical diagnosis in these difficult cases. 
Limitations of this study were the low number of 
patients, the short follow-up period and the lack of ma-
lignant lesions.
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